Haemonetics (HAE) Set to Release Earnings on Thursday

Haemonetics (NYSE:HAE) is expected to be releasing its Q2 2027 results before the market opens on Thursday, November 5th. Analysts expect Haemonetics to post earnings of $1.29 per share and revenue of $345.15 million for the quarter. Investors may review the information on the company’s upcoming Q2 2027 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.06. The business had revenue of $339.38 million for the quarter, compared to the consensus estimate of $327.86 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.10 earnings per share. On average, analysts expect Haemonetics to post $5.29 EPS for the current fiscal year and $5.73 EPS for the next fiscal year.

Haemonetics Trading Up 0.0%

Shares of HAE stock opened at $120.19 on Wednesday. The stock’s fifty day moving average is $110.48 and its two-hundred day moving average is $79.28. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. The firm has a market capitalization of $5.47 billion, a P/E ratio of 23.98, a PEG ratio of 2.40 and a beta of 0.63. Haemonetics has a fifty-two week low of $49.96 and a fifty-two week high of $123.77.

Analysts Set New Price Targets

HAE has been the subject of a number of research reports. Weiss Ratings raised shares of Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Raymond James Financial increased their target price on shares of Haemonetics from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, September 3rd. Robert W. Baird raised their price target on shares of Haemonetics from $96.00 to $119.00 and gave the stock an “outperform” rating in a research note on Friday, August 21st. Citigroup boosted their price target on shares of Haemonetics from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Finally, BTIG Research upped their price objective on shares of Haemonetics from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and a consensus price target of $110.00.

About Haemonetics

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.